MH048 / Minghui Pharma - LARVOL DELTA

Phase 1 dose escalation study of MH048, a novel and non-covalent BTK inhibitor in patients with relapsed or refractory B-cell malignancies. (ASCO 2022) - P1 | "Of the two MCL patients with PRs, one was heavily pretreated including ibrutinib prior to the enrollment. MH048 was well-tolerated and efficacy in heavily pre-treated patients with B-cell malignancies was observed. Pharmacokinetics studies suggest once-daily dosing. The dose expansion study is ongoing at 135 and 200 mg QD for CLL and MCL patients."

Clinical • P1 data • Anemia • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Hypertension • Marginal Zone Lymphoma • Oncology